sum
total
human
miseri
ascrib
viral
diseas
incalcul
viral
diseas
major
effect
histori
caus
death
war
combin
first
success
strategi
viral
infect
difficult
date
certainli
involv
empir
observ
fact
immun
survivor
certain
febril
diseas
smallpox
bear
scar
ill
forev
protect
diseas
diseas
origin
idea
deliber
induc
mild
form
diseas
protect
victim
contract
sever
form
led
strategi
vaccin
prevent
diseas
antivir
drug
interfer
life
cycl
viru
host
recent
origin
use
ground
knowledg
detail
virus
infect
damag
cell
virus
use
biochem
machineri
live
cell
replic
first
scientif
instanc
vaccin
infecti
diseas
occur
edward
jenner
draw
common
knowledg
histori
cowpox
never
develop
smallpox
inocul
cowpox
materi
skin
young
jame
phipp
local
boy
boy
later
inocul
fulli
virul
materi
smallpox
lesion
diseas
result
jenner
name
process
vaccin
vacca
latin
name
cow
first
publish
experi
vaccin
preced
similar
empir
procedur
variol
orient
practic
centuri
sinc
vaccin
develop
prevent
wide
rang
viral
diseas
tabl
basic
strategi
behind
vaccin
present
antigen
immun
system
way
stimul
immun
fulli
virul
organ
without
caus
diseas
vaccin
antigen
whole
attenu
inactiv
viru
protein
subunit
viru
process
way
similar
wildtyp
viru
vaccin
inject
viru
viral
protein
taken
macrophag
process
present
helper
lymphocyt
orchestr
immun
respons
immun
system
thu
prime
encount
wildtyp
viru
result
elimin
initi
two
basic
method
make
viral
strain
suitabl
vaccin
vaccin
strain
first
viru
inactiv
exposur
chemic
physic
agent
would
kill
viru
exampl
denatur
viral
protein
import
attach
invas
cell
viru
render
noninfecti
thu
inactiv
viru
replic
inactiv
vaccin
tend
less
reactogen
attenu
vaccin
advantag
revert
virul
form
salk
polio
vaccin
inactiv
treatment
viru
formalin
second
method
make
vaccin
strain
viru
attenu
serial
passag
cell
host
tissu
speci
result
product
viral
strain
specif
adapt
tissu
speci
therefor
less
virul
human
thu
vaccin
viru
caus
mild
infect
induc
immun
virul
wildtyp
viru
encount
natur
vaccin
potenti
disadvantag
revert
virul
form
exampl
sabin
polio
vaccin
three
strain
polioviru
serial
passag
monkey
kidney
tissu
cell
rare
case
revers
sabin
vaccin
strain
virul
form
case
paralyt
poliomyel
result
sever
method
produc
vaccin
develop
includ
subunit
vector
dna
vaccin
usual
given
parenter
variou
schedul
administr
use
subunit
vaccin
made
purifi
immunogen
viral
protein
incorpor
vaccin
singl
viral
protein
use
danger
inadvert
infect
viru
exampl
origin
hepat
b
vaccin
hepat
b
surfac
antigen
hbsag
purifi
blood
hepat
b
carrier
viral
protein
produc
recombin
dna
method
involv
human
blood
product
vector
vaccin
consist
rel
nonpathogen
viru
incorpor
gene
virul
viru
encod
antigen
protein
strategi
mild
infect
vector
viru
protein
dna
virul
viru
also
present
immun
system
without
actual
infect
virul
viru
advantag
vector
vaccin
dna
sever
differ
virul
virus
incorpor
immun
induc
one
virul
viru
vector
vaccin
current
avail
human
use
dna
vaccin
variat
vector
vaccin
theme
segment
viral
dna
code
immunogen
peptid
inject
directli
muscl
synthesi
peptid
occur
host
cell
peptid
express
surfac
cell
conjunct
type
major
histocompat
complex
molecul
recogn
immun
system
activ
prime
dna
vaccin
still
develop
none
avail
human
use
vaccin
effect
must
induc
appropri
immun
respons
gener
humor
cellmedi
immun
respons
made
vari
import
thu
specif
antibodi
inhibit
enterovirus
wherea
herpesvirus
suppress
cellmedi
immun
precis
type
immun
respons
protect
unknown
virus
howev
furthermor
inactiv
viru
viral
subunit
often
immunogen
gener
suffici
robust
immun
respons
adjuv
must
ad
vaccin
formul
adjuv
enhanc
immun
respons
variou
mean
attract
macrophag
induc
mild
inflamm
adjuv
freund
complet
adjuv
consist
miner
oil
nonviabl
mycobacteria
toxic
human
use
current
aluminum
salt
combin
aluminum
salt
phospholipid
use
recent
approv
bival
human
papilloma
viru
hpv
vaccin
adjuv
use
vaccin
human
use
safeti
consider
definit
import
includ
determin
advers
effect
vaccin
nonspecif
febril
reaction
inject
site
erythema
indur
allerg
reaction
vaccin
viru
vehicl
vaccin
viru
inadequ
inactiv
attenu
caus
diseas
intend
prevent
establish
safeti
vaccin
approv
human
use
critic
potenti
larg
popul
expos
rabi
viral
enceph
myeliti
usual
transmit
percutan
exposur
infect
saliva
rabid
anim
diseas
character
dramat
progress
neurolog
deficit
lead
cardiovascular
instabl
death
within
day
long
period
time
exposur
diseas
rare
north
america
elimin
domest
anim
pet
case
come
wildlif
infect
bat
throughout
rest
world
rabi
pose
seriou
burden
death
estim
annual
world
health
organ
idea
use
modifi
infecti
materi
protect
viral
diseas
adopt
pasteur
use
attenu
rabi
viru
infect
rabbit
spinal
cord
protect
dog
rabi
strategi
similar
produc
chicken
cholera
vaccin
take
infect
rabbit
spinal
cord
allow
dri
weaken
attenu
viru
present
cord
longer
dessic
weaker
viru
would
point
immun
reaction
induc
attenu
viru
would
prevent
infect
fulli
virul
viru
pasteur
vaccin
first
use
publicli
juli
young
boy
joseph
meister
multipl
bite
rabid
dog
administ
inject
period
surviv
origin
pasteur
vaccin
thu
cumbersom
administ
multipl
pain
inject
frequent
led
neurolog
complic
term
neuroparalyt
accid
fermi
vaccin
use
live
viru
attenu
phenol
sempl
vaccin
use
phenolinactiv
viru
contain
neural
tissu
howev
neuroparalyt
accid
remain
problem
fuenzalida
first
produc
myelinfre
vaccin
propag
viru
neonat
mous
brain
first
nonneur
tissuebas
vaccin
duck
embryo
vaccin
dev
consist
vaccin
viru
propag
duck
egg
introduc
although
incid
neuroparalyt
accid
greatli
reduc
dev
vaccin
immunogen
neural
tissuederiv
vaccin
requir
daili
inject
human
cell
use
develop
rabi
vaccin
free
anim
protein
human
diploid
cell
vaccin
contemporari
standard
first
develop
earli
wistar
institut
grow
pitmanmoor
strain
rabi
viru
human
cell
line
current
vaccin
produc
grow
pitmanmoor
strain
human
fibroblast
cell
line
inactiv
viru
supernat
bpropriolacton
inactiv
viru
concentr
vero
cell
purifi
chick
embryo
cell
also
use
grow
rabi
vaccin
viru
europ
unit
state
rabi
vaccin
usual
administ
postexposur
prophylaxi
part
specif
regimen
bite
wound
wash
soap
water
rabi
immun
globulin
infiltr
wound
vaccin
administ
defin
schedul
vaccin
safe
use
signific
reaction
rare
reaction
adult
consist
sore
site
inject
headach
malais
nausea
fewer
reaction
occur
children
allerg
reaction
human
diploid
cell
vaccin
occur
approxim
vaccine
rare
seriou
fatal
report
poliovirus
three
serotyp
enterovirus
usual
caus
mild
febril
ill
expos
children
polioviru
first
isol
landstein
popper
approxim
infect
result
poliomyel
patchi
involv
anterior
horn
cell
subsequ
weak
may
sever
perman
develop
polioviru
vaccin
epic
tale
fail
attempt
intens
scientif
research
rivalri
follow
introduct
two
differ
success
vaccin
erad
diseas
western
hemispher
prospect
global
erad
poliomyel
unrealist
first
attempt
vaccin
polioviru
plagu
inadequ
attenu
viru
actual
caus
diseas
trial
subject
much
need
learn
demonstr
three
distinct
poliovirus
achiev
test
attenu
virus
safeti
precaut
inject
neural
deriv
materi
scientif
develop
follow
year
led
import
realiz
viru
transmit
fecalor
contact
viru
replic
gut
spread
nervou
system
research
led
salk
vaccin
inactiv
polioviru
vaccin
administ
intramuscular
inject
sabin
vaccin
attenu
polioviru
vaccin
administ
oral
trial
salk
vaccin
begun
complet
done
first
unit
state
involv
approxim
million
subject
sabin
vaccin
trial
done
soon
afterward
soviet
union
wide
use
vaccin
essenti
elimin
poliomyel
western
hemispher
rate
poliomyel
unit
state
decreas
per
person
per
person
vaccin
entir
popul
promis
erad
diseas
worldwid
world
health
organ
made
prioriti
global
polio
erad
initi
final
erad
elus
measl
acut
febril
exanthem
caus
measl
viru
neg
sens
rna
viru
children
measl
recov
complet
diseas
complic
uncommon
includ
bacteri
superinfect
case
postvir
acut
dissemin
encephalomyel
adem
occur
fatal
leav
sever
neurolog
deficit
rare
viru
becom
establish
brain
million
case
lead
subacut
scleros
panenceph
progress
degen
diseas
brain
result
almost
alway
death
month
follow
latent
period
sever
year
measl
viru
first
isol
propag
tissu
cultur
ender
peebl
effort
make
measl
vaccin
follow
soon
thereaft
edmonston
strain
name
individu
first
isol
initi
viru
vaccin
made
edmonston
b
strain
actual
strain
use
vaccin
obtain
origin
edmonston
isol
serial
passag
primari
kidney
cell
passag
primari
human
amnion
cell
passag
chicken
embryo
passag
chicken
embryo
cell
vaccin
first
introduc
associ
high
rate
fever
rash
discontinu
vaccin
strain
much
better
toler
introduc
sever
year
discontinu
one
moraten
strain
introduc
deriv
edmonston
b
strain
addit
passag
chicken
embryo
cell
schwarz
strain
obtain
edmonston
b
strain
addit
passag
chicken
embryo
cell
use
moraten
vaccin
one
use
unit
state
today
vaccin
strain
use
elsewher
throughout
world
effect
vaccin
may
gaug
fact
vaccin
million
case
measl
occur
annual
unit
state
wherea
case
difficulti
measl
vaccin
develop
demonstr
formalininactiv
measl
vaccin
prepar
edmonston
strain
use
unit
state
vaccin
provid
shortterm
protect
measl
left
recipi
vulner
infect
measl
viru
clinic
form
measl
take
patient
atyp
sever
mark
sudden
onset
fever
headach
dri
cough
myalgia
abdomin
pain
follow
rash
begin
distal
extrem
patient
develop
pneumonia
resolv
slowli
patient
atyp
measl
high
titer
antibodi
mani
viral
protein
viral
fusion
protein
f
protein
thought
formalin
inactiv
viru
render
f
protein
nonimmunogen
thu
allow
celltocel
spread
result
widespread
diseas
use
vaccin
discontinu
mump
viru
paramyxoviru
caus
acut
pain
parot
children
diseas
usual
selflimit
complic
mening
meningoenceph
residu
deficit
also
result
sensorineur
deaf
adult
mump
higher
rate
system
complic
caus
orchiti
adult
men
oophor
mastiti
substanti
proport
adult
women
organ
may
involv
well
viru
first
mump
vaccin
obtain
young
girl
name
jeryl
lynn
daughter
master
vaccinologist
mauric
hilleman
passag
embryon
hen
egg
chick
embryo
cell
cultur
urab
strain
obtain
japanes
patient
jeryl
lynn
strain
vaccin
test
two
clinic
trial
one
philadelphia
nurseri
school
kindergarten
children
one
forsyth
counti
north
carolina
schoolchildren
mump
vaccin
first
licens
use
number
case
mump
unit
state
decreas
case
number
case
increas
briefli
vaccin
rate
declin
decreas
mump
vaccin
requir
school
entri
case
rubella
selflimit
febril
exanthemat
diseas
children
caus
envelop
rna
viru
toga
viru
famili
viru
link
norman
gregg
congenit
cataract
offspr
mother
rubella
pregnanc
later
realiz
rubella
pregnanc
could
lead
multipl
birth
defect
neurolog
includ
deaf
blind
microcephali
subsequ
mental
retard
motor
languag
difficulti
diseas
complic
arthriti
case
postvir
adem
rare
acut
diseas
may
follow
month
year
later
progress
rubella
panenceph
progress
degen
diseas
lead
death
within
month
viru
isol
two
differ
group
sever
vaccin
strain
develop
one
current
use
strain
live
viru
vaccin
viru
first
isol
tissu
fetu
serial
passag
human
diploid
cell
line
two
differ
temperatur
shown
attenu
inocul
human
volunt
passag
increas
attenu
human
diploid
cell
line
vaccin
given
combin
measl
mump
vaccin
vaccin
rubella
exceedingli
success
incid
rate
decreas
approxim
case
per
person
vaccin
licens
case
unit
state
incid
congenit
rubella
syndrom
decreas
averag
case
per
year
unit
state
case
born
outsid
unit
state
varicella
chicken
pox
acut
febril
selflimit
exanthemat
diseas
children
caus
varicellazost
viru
vzv
member
herpesviru
famili
complic
diseas
includ
varicella
pneumonia
hepat
cerebellar
ataxia
enceph
diseas
tend
sever
adult
immunocompromis
well
pregnant
women
previous
mention
complic
common
acut
infect
viru
assum
latent
state
sensori
ganglia
reactiv
host
age
host
immunocompromis
reactiv
result
shingl
zoster
pain
vesicular
erupt
locat
dermatom
spinal
nerv
root
reactiv
occur
pain
shingl
quit
sever
prolong
occasion
year
episod
shingl
result
postherpet
neuralgia
shingl
common
affect
popul
live
ninth
decad
shingl
affect
distribut
trigemin
nerv
caus
ophthalm
zoster
blind
potenti
complic
reactiv
vzv
sensori
ganglia
also
involv
spinal
cord
result
myeliti
varicella
viru
vaccin
strain
origin
obtain
boy
whose
last
name
oka
otherwis
uncompl
chicken
pox
viru
isol
primari
human
embryon
lung
fibroblast
helf
cell
cultur
serial
passag
multipl
cell
line
sonic
releas
free
viru
result
vaccin
oka
strain
viru
found
temperatur
sensit
less
pathogen
skin
explant
wildtyp
viru
also
differ
dna
cleavag
pattern
vaccin
oka
wildtyp
strain
viru
clinic
trial
oka
vaccin
strain
began
japan
vaccin
first
given
normal
children
found
immunogen
protect
signific
side
effect
safeti
attenu
vaccin
strain
demonstr
children
chronic
medic
condit
subsequ
studi
japan
show
vaccin
safe
use
children
leukemia
malign
chemotherapi
stop
week
vaccin
resum
week
studi
unit
state
show
children
cancer
kidney
transplant
vaccin
safe
although
two
dose
need
guarante
optim
protect
chicken
pox
vaccin
licens
unit
state
use
healthi
children
adult
appropri
precaut
children
leukemia
renal
diseas
vaccin
may
help
prevent
shingl
elderli
boost
antivzv
immun
use
recommend
rare
case
shingl
involv
vaccin
viru
report
arbovirus
virus
transmit
arthropod
mosquito
tick
therefor
taxonom
group
rather
ecolog
classif
arbovir
infect
may
asymptomat
caus
febril
rash
polyarthr
hemorrhag
fever
enceph
exampl
latter
includ
st
loui
enceph
western
equin
enceph
eastern
equin
enceph
lacross
enceph
west
nile
enceph
north
america
venezuelan
equin
enceph
south
america
japanes
enceph
je
southeast
asia
murray
valley
enceph
kunjin
fever
australia
tickborn
enceph
tbe
europ
far
east
je
avir
enceph
endem
southeast
asia
caus
flaviviru
transmit
mosquito
diseas
first
describ
japan
epidem
result
case
fatal
sinc
outbreak
occur
china
korea
vietnam
india
recent
malaysia
indonesia
papua
new
guinea
northern
australia
risk
diseas
unvaccin
neglig
suscept
us
british
australian
militari
personnel
station
endem
area
incid
rate
je
increas
approxim
case
per
week
per
viru
first
isol
human
brain
inocul
rabbit
diseas
transmit
monkey
sever
vaccin
made
sinc
current
three
vaccin
common
use
southeast
asia
two
inactiv
one
deriv
mous
brain
primari
hamster
kidney
cell
attenu
vaccin
obtain
primari
hamster
kidney
cell
nakayama
strain
use
inactiv
mous
brainderiv
vaccin
special
treat
remov
myelin
basic
protein
formul
risk
postvaccin
adem
minim
case
adem
link
vaccin
report
estim
risk
small
less
one
case
per
million
vaccine
efficaci
vaccin
je
demonstr
sever
studi
conduct
southeast
asia
nakayama
vaccin
shown
effect
taiwanes
studi
thai
studi
effect
monoval
nakayama
bival
nakayama
vaccin
found
import
je
vaccin
public
health
highlight
fact
includ
thai
expand
program
immun
children
fourth
dose
diphtheriapertussistetanu
dpt
oral
polio
vaccin
institut
month
japan
case
je
year
vaccin
avail
number
case
decreas
near
zero
soon
vaccin
institut
beij
annual
incid
rate
je
case
per
person
per
year
vaccin
avail
incid
rate
decreas
approxim
case
per
person
rate
decreas
less
per
person
tbe
diseas
first
describ
preval
central
europ
far
east
viru
first
isol
zilber
cowork
soviet
union
clinic
diseas
may
biphas
initi
period
fever
malais
headach
backach
nausea
follow
afebril
period
sever
day
week
fever
resum
along
headach
confus
paresi
seizur
case
coma
tropism
viru
anterior
horn
cell
surviv
patient
often
left
paralysi
neck
shoulder
girdl
muscl
inde
far
eastern
area
former
soviet
union
individu
must
prop
head
almost
alway
victim
tbe
central
european
form
diseas
less
virul
far
eastern
form
mortal
rate
report
older
patient
tend
sever
form
diseas
risk
infect
suscept
us
militari
personnel
live
highli
endem
area
estim
case
per
per
month
earli
first
vaccin
tbe
produc
use
inactiv
viru
prepar
infect
mous
brain
given
soviet
militari
personnel
result
numer
complic
subsequ
vaccin
produc
viru
grown
chicken
embryo
cell
inactiv
formalin
current
vaccin
use
central
europ
made
viru
deriv
tick
passag
serial
mous
brain
chicken
embryo
inactiv
formalin
purifi
sucros
densiti
gradient
centrifug
although
random
control
clinic
trial
tbe
vaccin
done
seroconvers
demonstr
occur
vaccine
threedos
vaccin
schedul
tbe
vaccin
use
central
europ
voluntari
basi
rather
incorpor
requir
vaccin
schedul
approxim
million
dose
administ
austria
sinc
vaccin
becam
avail
measur
use
vaccin
infer
decreas
incid
diseas
vaccin
came
gener
use
number
case
tbe
austria
decreas
case
part
europ
may
increas
vaccin
eastern
western
venezuelan
equin
enceph
avail
us
militari
personnel
veterinari
laboratori
staff
gener
public
three
virus
passag
chicken
embryo
cell
addit
passag
eastern
equin
enceph
viru
mice
guinea
pig
inactiv
formalin
influenza
influenza
acut
febril
debilit
though
usual
selflimit
viral
infect
upper
respiratori
tract
caus
signific
work
school
absenc
year
elderli
chronic
ill
prone
develop
complic
pneumonia
lethal
influenza
complic
adem
children
encephalopathi
includ
rey
syndrom
diseas
occur
yearli
epidem
midwint
everi
decad
complet
new
strain
appear
caus
pandem
strain
deadli
influenza
pandem
caus
ten
million
death
worldwid
dwarf
mortal
concurr
world
war
pandem
seriou
lethal
consequ
pandem
viru
first
isol
smith
andrew
laidlaw
neutral
antibodi
detect
subject
given
subcutan
inject
influenza
viru
stoke
et
al
demonstr
degre
protect
perform
first
trial
influenza
vaccin
viru
grown
suspens
mous
lung
inject
children
studi
influenza
vaccin
carri
us
armi
begin
use
inactiv
influenza
viru
benefit
vaccin
clearcut
studi
led
licens
influenza
vaccin
civilian
popul
dramat
failur
vaccin
influenza
epidem
found
vaccin
produc
immun
vaccin
viru
epidem
strain
epidem
strain
differ
antigen
vaccin
strain
illustr
effect
antigen
chang
known
occur
influenza
viru
two
type
chang
antigen
drift
accumul
mutat
gene
code
surfac
antigen
viru
render
suffici
differ
previou
strain
caus
diseas
despit
exposur
previou
viru
antigen
shift
reassort
gene
code
surfac
protein
origin
new
genet
materi
seem
strain
circul
bird
experi
led
establish
worldwid
sentinel
center
world
health
organ
monitor
new
strain
influenza
viru
everi
year
new
strain
incorpor
updat
vaccin
import
activ
new
pandem
expect
occur
futur
recent
activ
concern
pandem
influenza
socal
swine
flu
addit
highli
pathogen
strain
avian
flu
emerg
although
case
human
requir
contact
sick
poultri
high
mortal
rate
peopl
current
vaccin
use
two
strain
influenza
viru
one
influenza
b
viru
grown
embryon
chicken
egg
yellow
fever
caus
flaviviru
transmit
mosquito
rang
subclin
infect
mild
flulik
ill
fulmin
diseas
character
high
fever
liver
failur
jaundic
henc
name
yellow
fever
oligur
renal
failur
hemorrhag
diathesi
hematemesi
diseas
respons
massiv
epidem
unit
state
eighteenth
nineteenth
centuri
exampl
epidem
yellow
fever
philadelphia
kill
popul
viru
first
isol
blood
ghanaian
patient
name
asibi
asibi
strain
variou
inactiv
vaccin
develop
unsuccess
max
theiler
work
rockefel
institut
new
york
develop
first
success
yellow
fever
vaccin
serial
passag
asibi
strain
embryon
hen
egg
vaccin
strain
strain
attenu
vaccin
first
test
rapidli
distribut
thu
million
brazilian
receiv
vaccin
separ
control
yellow
fever
french
africa
achiev
vaccin
one
safest
known
rare
case
enceph
young
infant
led
recommend
infant
younger
month
age
given
vaccin
hiv
diseas
caus
human
immunodefici
viru
hiv
envelop
doubli
segment
posit
sens
rna
viru
viru
infect
cluster
differenti
tlymphocyt
caus
destruct
period
approxim
year
initi
infect
howev
tcell
replenish
gradual
extinguish
precis
pathogenesi
destruct
cell
unknown
result
destruct
cell
immunodefici
subsequ
develop
numer
opportunist
infect
diseas
also
caus
chronic
inflammatori
state
weight
loss
fever
night
sweat
also
sever
progress
neurolog
condit
link
hiv
infect
includ
hiv
dementia
myelopathi
distal
sensori
neuropathi
hiv
diseas
becom
pandem
million
peopl
die
acquir
immunodefici
syndrom
aid
worldwid
sinc
estim
million
peopl
infect
hiv
worldwid
number
continu
increas
especi
third
world
countri
potent
antiretrovir
drug
introduc
therapi
diseas
origin
limit
affluent
societi
western
europ
north
america
recent
made
avail
third
world
practic
way
prevent
spread
diseas
vaccin
despit
intens
work
vaccin
numer
difficulti
delay
develop
effect
immun
success
vaccin
essenti
abolish
childhood
diseas
poliomyel
measl
hemophilu
influenza
type
b
infect
diphtheria
whoop
cough
tetanu
mump
rubella
preval
us
popul
sever
decad
ago
protect
popul
viral
diseas
vaccin
specif
diseas
endem
popul
use
north
america
vaccin
poliomyel
influenza
measl
mump
rubella
varicella
hepat
b
use
europ
addit
protect
may
necessari
central
european
tbe
asia
protect
je
import
protect
special
popul
veterinarian
chronic
ill
militari
personnel
laboratori
worker
travel
mandat
use
vaccin
necessari
gener
popul
thu
chronic
ill
consider
morbid
mortal
influenza
frequent
vaccin
annual
influenza
viru
strain
circul
year
veterinarian
laboratori
worker
may
expos
rabi
vaccin
militari
personnel
station
area
world
certain
infect
endem
need
vaccin
eg
je
southeast
asia
certain
human
viral
diseas
present
attract
target
erad
uniqu
characterist
virus
candid
erad
viru
must
reservoir
natur
exist
latent
form
human
reactiv
infect
naiv
host
vaccin
must
produc
complet
longlast
immun
viral
genom
must
stabl
variant
previous
infect
popul
suscept
aris
thu
smallpox
poliomyel
rubella
measl
candid
erad
smallpox
alreadi
erad
world
health
organ
made
erad
poliomyel
prioriti
measl
devast
children
develop
countri
also
potenti
candid
erad
rabi
anim
reservoir
erad
immun
rhinovirus
shortliv
therefor
common
cold
unlik
erad
influenza
viru
genet
stabl
new
variant
aris
yearli
influenza
epidem
occur
everi
year
pandem
occur
everi
decad
cutter
incid
potenti
problem
vaccin
contain
attenu
viru
possibl
insuffici
attenu
dramat
exampl
occur
earli
day
salk
polio
vaccin
vaccin
individu
contact
develop
poliomyel
case
occur
vaccine
occur
famili
contact
occur
casual
contact
commun
case
could
attribut
patient
acquir
natur
infect
vaccin
thu
develop
diseas
vaccin
provid
effect
immun
polio
case
occur
western
state
suppli
singl
vaccin
manufactur
anoth
clue
vaccinerel
case
observ
inject
limb
tend
affect
weak
problem
trace
lot
vaccin
one
manufactur
inadequ
attenu
vaccin
lot
withdrawn
vaccin
manufactur
found
safe
sabin
attenu
vaccin
effect
protect
poliomyel
attenu
polioviru
vaccin
replic
gastrointestin
tract
stimul
mucos
immun
viru
attenu
vaccin
viru
excret
stool
may
infect
close
contact
vaccine
thu
vaccin
well
howev
vaccin
viru
attenu
undergo
replic
gut
possibl
revers
virul
form
unfortun
possibl
rare
realiz
sabin
vaccin
caus
paralyt
poliomyel
vaccine
contact
approxim
one
case
per
million
dose
risk
accept
poliomyel
endem
popul
longer
case
north
america
accordingli
use
sabin
vaccin
discontinu
inactiv
polioviru
vaccin
deliv
inocul
recommend
origin
rabi
vaccin
plagu
characterist
advers
event
known
neuroparalyt
accid
sever
adem
acut
inflammatori
demyelin
brain
spinal
cord
molecular
mimicri
thought
like
mechan
vaccin
antigen
resembl
myelin
antigen
immun
reaction
trigger
myelin
insul
axon
nervou
system
subsequ
destruct
myelin
failur
conduct
impuls
nervou
system
adem
often
lead
cognit
motor
deficit
survivor
vaccin
inadvert
contamin
vaccin
virul
viru
deduc
observ
case
surviv
wherea
rabi
alway
fatal
patholog
surviv
differ
seen
rabi
rabi
viru
could
isol
brain
fatal
afflict
complic
believ
instead
crossreact
myelin
contain
vaccin
note
previous
method
prepar
develop
produc
myelinfre
vaccin
indic
particularli
virul
strain
influenza
viru
swine
flu
circul
massiv
campaign
vaccin
strain
nation
immun
program
mount
unit
state
soon
thereaft
sever
case
syndrom
acut
inflammatori
polyneuropathi
report
vaccin
recipi
care
studi
case
led
estim
risk
syndrom
swine
flu
vaccin
case
per
million
excess
syndrom
attribut
influenza
vaccin
also
occur
season
time
rel
risk
per
one
million
develop
syndrom
found
clear
risk
specif
influenza
vaccin
howev
report
associ
measlesmumpsrubella
mmr
vaccin
develop
autism
inflammatori
bowel
diseas
engend
much
controversi
twelv
children
report
develop
cognit
problem
day
month
receiv
mmr
vaccin
howev
age
mmr
vaccin
administ
also
age
autism
becom
appar
furthermor
populationbas
studi
control
estim
rel
risk
autism
follow
vaccin
final
year
detail
conduct
studi
rais
seriou
question
regard
integr
paper
retract
report
children
report
develop
sever
encephalopathi
intract
seizur
follow
dpt
vaccin
review
interpret
extant
data
institut
medicin
show
insuffici
evid
link
vaccin
perman
neurolog
damag
howev
may
slight
risk
acut
encephalopathi
follow
vaccin
excess
risk
per
million
vaccin
recipi
patient
dravet
syndrom
pediatr
epilept
encephalopathi
usual
sodium
channel
gene
mutat
manifest
intract
seizur
age
children
vaccin
may
spuriou
associ
furthermor
origin
dpt
vaccin
contain
kill
whole
cell
pertussi
reactogen
caus
discomfort
fever
could
turn
caus
febril
seizur
sinc
adopt
acellular
pertussi
compon
dpt
vaccin
fewer
reaction
occur
attenu
virus
may
rare
associ
seriou
clinic
ill
immunosuppress
ill
may
affect
nervou
system
occur
remot
time
vaccin
case
measl
inclus
bodi
enceph
occur
month
vaccin
mmr
report
vaccinestrain
viru
isol
brain
investig
reveal
previous
undiscov
immunodefici
oka
vaccin
strain
vzv
caus
dissemin
varicella
asept
mening
patient
fourth
week
chemotherapi
neuroblastoma
histori
develop
antivir
drug
dramat
vaccin
replic
virus
mammalian
cell
intim
involv
biochem
pathway
use
cell
interfer
viral
replic
often
result
unaccept
toxic
furthermor
understand
cellular
biochemistri
long
gradual
process
long
time
virusspecif
target
elus
inde
mani
current
use
antivir
drug
origin
investig
cancer
chemotherapi
agent
first
trial
antivir
use
anticanc
drug
nonretrovir
virus
effect
agent
shown
tabl
antivir
therapi
must
shown
effect
properli
design
clinic
trial
involv
mani
subject
therefor
must
carri
multipl
close
collabor
center
nation
institut
allergi
infecti
diseas
exampl
organ
much
work
done
herpesviru
therapi
umbrella
collabor
antivir
studi
group
casg
establish
role
acyclovir
treatment
herp
simplex
enceph
landmark
achiev
mani
studi
antiretrovir
therapi
done
aegi
aid
clinic
trial
group
actg
neuroaid
research
consortium
sponsor
sever
studi
antivir
agent
treatment
neurolog
complic
aid
step
viral
life
cycl
cell
provid
potenti
therapeut
target
viru
attach
cell
penetr
replic
viral
nucleic
acid
protein
synthes
nucleic
acid
packag
protein
virion
releas
initi
cycl
anoth
cell
viral
life
cycl
uniqu
featur
attract
antivir
target
consequ
antivir
agent
tend
target
close
relat
virus
tabl
dna
replic
one
first
aspect
molecular
biolog
cell
explor
surpris
antivir
strategi
initi
focus
part
viral
life
cycl
thu
dna
virus
herpesvirus
use
cellular
precursor
molecul
replic
dna
dna
compos
deoxynucleosid
triphosph
dntp
deoxynucleosid
pyrimidin
base
deoxyribos
viral
program
enzym
use
cellular
dntp
synthes
viral
dna
acyclovir
guanidin
analog
deoxyribos
replac
acycl
structur
origin
synthes
elion
hitch
first
design
drug
specif
design
purpos
inhibit
dna
synthesi
viral
polymeras
acyclovir
two
mechan
action
first
inhibit
viral
dna
polymeras
competit
bind
activ
site
enzym
second
acyclovir
insert
grow
dna
chain
termin
elong
acyclovir
must
tripli
phosphoryl
activ
acyclovir
first
monophosphoryl
viral
encod
thymidin
kinas
subsequ
phosphoryl
cellular
enzym
thu
acyclovir
activ
viral
infect
cell
acyclovir
effect
herp
simplex
vzv
infect
herpesviru
infect
gancyclovir
anoth
guanidin
analog
notabl
effect
cytomegaloviru
cmv
acyclovir
one
first
agent
shown
effect
treatment
herp
simplex
enceph
origin
studi
idoxuridin
cytarabin
cancer
chemotherapeut
agent
herp
enceph
show
drug
ineffect
idoxuridin
found
toxic
vidarabin
investig
casg
unit
state
public
shown
efficaci
reduct
mortal
rate
placebo
group
vidarabin
group
insolubl
requir
intraven
administr
larg
volum
fluid
casg
studi
efficaci
acyclovir
vidarabin
found
mortal
rate
acyclovir
group
compar
vidarabin
group
ribavirin
guanosin
analog
antivir
effect
mani
virus
rna
dna
mechan
action
complet
clear
although
part
competit
guanosin
may
also
inhibit
synthesi
guanosin
deplet
pool
guanosin
triphosph
avail
viral
nucleic
acid
synthes
apparatu
drug
effect
influenza
parainfluenza
respiratori
syncyti
virus
rsv
limit
effect
adenovirus
coxsacki
viru
rhino
coronavirus
therapeut
use
lassa
fever
hemorrhag
fever
renal
syndrom
conjunct
ainterferon
drug
activ
hepat
c
drug
avail
aerosol
form
rsv
infect
infant
parenter
form
avail
use
compassion
basi
certain
exot
viral
infect
lassa
fever
hantaviru
pulmonari
syndrom
dna
replic
involv
sequenti
addit
nucleotid
grow
dna
chain
involv
cleavag
dntp
deoxynucleosid
monoand
pyrophosph
pyrophosph
analog
prevent
cleavag
thu
inhibit
viral
replic
foscarnet
pyrophosph
analog
approv
treatment
herpesviru
infect
specif
cmv
infect
drug
effect
herpesvirus
addit
replic
hiv
also
inhibit
import
step
influenza
viru
infect
releas
viral
rna
viru
cell
nucleu
virion
enter
cell
held
vesicl
acidifi
attempt
destroy
viru
hydrogen
ion
bath
viru
direct
viral
envelop
proton
channel
protein
known
insid
virion
allow
viral
rna
dissoci
intern
scaffold
viru
viral
rna
transport
cell
nucleu
blocker
channel
form
protein
prevent
dissoci
therebi
prevent
replic
viru
mechan
action
two
drug
current
market
amantadin
rimantadin
use
prevent
treatment
influenza
neuraminidas
enzym
use
bud
influenza
viru
escap
surfac
infect
cell
neuraminidas
inhibitor
prevent
escap
therefor
viru
releas
infect
cell
viral
spread
cell
prevent
diseas
durat
symptom
improv
neuraminidas
inhibitor
approv
use
treatment
influenza
b
includ
zanamivir
oseltamivir
addit
oseltamivir
shown
prevent
diseas
risk
receiv
food
drug
administr
fda
approv
use
enteroviru
infect
viru
attach
suscept
cell
slightli
unusu
mechan
viru
consist
viral
rna
surround
icosahedr
capsid
capsid
consist
protom
consist
viral
protein
surfac
surfac
surfac
depress
call
canyon
intercellular
adhes
suscept
cell
bind
bind
occur
viru
enter
cell
capsid
undergo
reconfigur
disassembl
releas
viral
nucleic
acid
seri
compound
known
win
compound
design
molecular
model
bind
canyon
floor
inhibit
bind
viru
cell
also
prevent
releas
viral
rna
cytoplasm
cell
one
compound
pleconaril
test
clinic
trial
develop
proceed
drug
excel
central
nervou
system
penetr
trial
drug
enterovir
mening
way
unfortun
seem
effect
enteroviru
caus
sever
neurolog
complic
case
hand
foot
mouth
diseas
childhood
first
antiretrovir
drug
revers
transcriptas
rt
inhibitor
introduc
clinic
practic
zidovudin
origin
investig
anticanc
drug
jerom
horwitz
detroit
unsuccess
languish
laboratori
shelf
screen
test
suggest
use
antiretrovir
drug
initi
clinic
trial
compar
drug
placebo
demonstr
surviv
benefit
short
term
drug
licens
use
aid
antiretrovir
drug
follow
initi
hope
short
live
two
main
difficulti
use
antiretrovir
drug
becam
quickli
appar
toxic
drug
fact
viral
resist
drug
occur
readili
viru
replic
rapidli
resist
mutat
aris
readili
rt
errorpron
replic
enzym
estim
virion
produc
daili
hiv
infect
nucleotid
base
hiv
genom
rate
mutant
aris
high
inde
singl
hiv
virion
give
rise
larg
number
viral
variant
swarm
quasispeci
mani
viral
variant
resist
whatev
antiretrovir
agent
patient
take
therefor
initi
good
respons
drug
last
month
prompt
strategi
combin
therapi
sever
drug
differ
mechan
action
use
simultan
viral
replic
maxim
suppress
opportun
resist
viral
variant
minim
drug
toxic
use
care
retrovirus
revers
transcrib
rna
genom
dna
copi
import
target
therapeut
intervent
rt
present
normal
cell
led
idea
use
nucleosid
analog
would
bind
specif
rt
nucleosid
rt
inhibitor
nrti
zidovudin
first
drug
introduc
follow
didanosin
zalcitabin
nrti
list
tabl
nucleosid
analog
bind
activ
site
rt
molecul
anoth
class
rt
inhibitor
compos
drug
bind
rt
site
away
activ
site
inhibit
function
alloster
mechan
nonnrti
nucleosid
analog
includ
nevirapin
delavirdin
efavirenz
combin
nrti
especi
potent
antiretrovir
effect
incorpor
singl
capsul
exampl
combin
zidoand
lamivudin
market
combivir
toxic
zidovudin
includ
anemia
neutropenia
myopathi
toxic
didanosin
zalcitabin
includ
pain
peripher
neuropathi
pancreat
inde
zalcitabin
longer
use
life
cycl
hiv
involv
bud
immatur
virion
infect
cell
undergo
process
matur
mediat
cleavag
viral
protein
particularli
cleavag
prevent
cleavag
render
virion
unabl
infect
suscept
cell
viral
proteas
accomplish
cleavag
therefor
potenti
target
antivir
drug
form
class
proteas
inhibitor
drug
design
specif
target
hiv
proteas
use
computeraid
molecular
model
first
drug
introduc
saquinavir
other
list
tabl
standard
combin
one
drug
boost
blood
level
ritonavir
lopinavir
market
kaletra
thu
advantag
taken
would
otherwis
annoy
drug
interact
proteas
inhibitor
use
care
patient
use
medic
complic
interact
liver
enzym
also
contribut
abnorm
carbohydr
lipid
metabol
may
trigger
diabet
peculiar
form
lipid
redistribut
expand
treatment
option
provid
new
drug
transform
aid
epidem
chronic
diseas
enfuvirtid
peptid
interfer
fusion
viral
cellular
membran
prevent
viral
penetr
cell
thu
abrog
step
infect
cell
given
subcutan
inject
infect
cell
hiv
viru
must
bind
cell
main
receptor
well
coreceptor
main
coreceptor
use
maraviroc
block
bind
former
prevent
infect
infect
viru
tropism
determin
baselin
laboratori
evalu
patient
one
step
hiv
infect
cell
manufactur
complementari
dna
cdna
copi
viral
genom
integr
host
cell
genom
involv
seri
configur
shift
catalyz
integras
raltegravir
block
integras
viru
integr
genom
cell
hepat
b
circular
partial
doublestrand
dna
viru
usual
caus
acut
hepat
resolut
small
proport
patient
develop
chronic
hepat
often
lead
cirrhosi
hepatocellular
carcinoma
part
world
endem
signific
caus
morbid
mortal
strategi
use
nucleosid
analog
block
rt
hiv
infect
adopt
treatment
activ
replic
hepat
b
viru
hbv
part
life
cycl
viru
involv
revers
transcript
origin
hepat
b
treat
longterm
pegyl
interferona
ifna
administ
inject
efficaci
side
effect
drug
limit
use
sever
rt
inhibitor
drug
approv
treatment
hepat
b
includ
lamivudin
adefovir
tenofovir
also
use
hiv
recent
entecavir
telbivudin
specif
approv
hepat
b
hepat
c
viru
rna
viru
caus
chronic
hepat
often
result
cirrhosi
hepatocellular
carcinoma
hepat
b
viru
present
worldwid
bloodborn
although
transmiss
alway
clear
particular
case
infect
initi
often
asymptomat
sever
diseas
present
patient
consult
physician
diseas
treat
longact
pegyl
ifna
along
ribavirin
toxic
regimen
limit
efficaci
variabl
respons
base
hepat
c
viru
hcv
genotyp
analog
proteas
inhibitor
hiv
diseas
potenti
target
proteas
function
necessari
viral
replic
viral
genom
translat
polyprotein
process
cleavag
nonstructur
serin
proteas
lead
gener
protein
result
viabl
replicationcompet
viru
agent
telaprevir
boceprevir
serin
proteas
inhibitor
block
action
stop
viral
replic
recent
approv
fda
treatment
chronic
hepat
c
new
discoveri
molecular
virolog
occur
breakneck
pace
open
possibl
treatment
